|
Index of reports
> Hospitalization (735)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to PEG-Intron (Peginterferon Alfa-2B) hospitalization. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 735 Next >>
Possible PEG-Intron side effects in 59 year old female
Reported by a physician from Canada on 2012-08-27
Patient: 59 year old female, weighing 44.0 kg (96.8 pounds)
Reactions: Oesophageal Varices Haemorrhage, Ascites
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Incivek
Dosage: 750 mg, tid
Administration route: Oral
Indication: Hepatitis C
PEG-Intron
Dosage: 120 unk, unk
Indication: Hepatitis C
Other drugs received by patient: Nadolol; Lasix; Atenolol; Spironolactone; Eprex
Possible PEG-Intron side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-27
Patient:
Reactions: Malaise, Renal Impairment, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, unk
Indication: Hepatitis C
Start date: 2012-06-06
Rebetol
Dosage: 600 mg, unk
Administration route: Oral
Start date: 2012-06-15
End date: 2012-06-20
Rebetol
Dosage: 200 mg, unk
Administration route: Oral
Start date: 2012-06-21
End date: 2012-07-12
Rebetol
Dosage: 800 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-06
End date: 2012-06-14
Rebetol
Dosage: 200 mg, qod
Administration route: Oral
Start date: 2012-07-13
Telavic
Dosage: 1500 mg, unk
Administration route: Oral
Start date: 2012-06-08
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-06
End date: 2012-06-07
Other drugs received by patient: Lendormin; Lansoprazole; Amoban
Possible PEG-Intron side effects in female
Reported by a consumer/non-health professional from United States on 2012-08-27
Patient: female
Reactions: Dehydration, Anaemia, Lower Respiratory Tract Inflammation
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: unk
Indication: Hepatitis C
Start date: 2012-02-15
Ribavirin
Dosage: unk
Indication: Hepatitis C
Start date: 2012-02-15
VX-950
Dosage: 750 mg, tid
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-15
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-27
Patient:
Reactions: Rash
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, unk
Start date: 2012-06-19
Rebetol
Dosage: 600 mg, unk
Administration route: Oral
Start date: 2012-06-19
Rebetol
Dosage: 400 mg, unk
Administration route: Oral
Start date: 2012-07-03
Telavic
Dosage: 2250 mg, unk
Administration route: Oral
Start date: 2012-06-19
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-27
Patient:
Reactions: Anaemia, Rash, Haemolytic Anaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-31
End date: 2012-03-16
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-01-31
End date: 2012-03-15
Ribavirin
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-04-24
End date: 2012-05-21
Ribavirin
Dosage: 500 mg, qd
Administration route: Oral
Start date: 2012-05-22
Ribavirin
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-03-21
End date: 2012-04-03
Ribavirin
Dosage: 400 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-31
End date: 2012-02-27
Ribavirin
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-02-28
End date: 2012-03-17
Ribavirin
Dosage: 300 mg, qd
Administration route: Oral
Start date: 2012-04-04
End date: 2012-04-23
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-31
End date: 2012-03-16
Other drugs received by patient: Coniel; Famotidine; Allopurinol; Celestamine (Betamethasone (+) Dexchlorpheniramine Maleate (+) Fluphen; Isosorbide Dinitrate
Possible PEG-Intron side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-27
Patient:
Reactions: Pancreatitis Acute, Anaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-05-11
End date: 2012-06-15
Rebetol
Dosage: 800 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-11
End date: 2012-06-20
Telaprevir
Dosage: 2250 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-11
End date: 2012-06-20
Other drugs received by patient: Talion (Bepotastine Besylate); Feburic; Famostagine D; NEO-Minophagen C; Urdeston; Trebianom; Sitagliptin Phosphate
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-27
Patient:
Reactions: Interstitial Lung Disease, Oedema, Hepatic Failure
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bactrim
Dosage: 1 df, once
Administration route: Oral
Indication: Adverse Event
End date: 2012-06-09
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-03-13
End date: 2012-04-04
Rebetol
Dosage: 800 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-13
End date: 2012-04-04
Telavic
Dosage: 2250 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-13
End date: 2012-04-04
Other drugs received by patient: Urso 250; Lasix; Celestamine TAB; NEO-Minophagen C; Aldactone
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-27
Patient:
Reactions: Renal Impairment, Anaemia, Pancreatitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-04-27
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-27
End date: 2012-05-24
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-05-25
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-27
End date: 2012-05-17
Other drugs received by patient: Antebate; Prednisolone; Dexaltin; Ubiron; Aspara CA; Loxonin; Onealfa; Diovan; Berizym (Lysozyme Chloride); Mirobect; Amlodipine; Isoleucine (+) Leucine (+) Valine; Lansoprazole; Mucosta
Possible PEG-Intron side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-27
Patient:
Reactions: Drug Eruption, Haemoglobin Decreased, Malaise, Hyperglycaemia, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-05-17
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-17
End date: 2012-06-13
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-06-14
End date: 2012-06-28
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-07-18
End date: 2012-07-26
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-17
End date: 2012-05-25
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Other drugs received by patient: Motilium; Gasmotin; Diflorasone Diacetate; Nizatidine
Possible PEG-Intron side effects in
Reported by a pharmacist from Japan on 2012-08-25
Patient:
Reactions: Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 0.75 microgram per kilogram, unk
Start date: 2012-07-16
PEG-Intron
Dosage: 1.5mcg/kg
Start date: 2012-07-09
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Start date: 2012-07-09
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Start date: 2012-07-09
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-07-13
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-25
Patient:
Reactions: Pleurisy
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 100 microgram per kilogram, 5 times a week
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Possible PEG-Intron side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-25
Patient:
Reactions: Rash Erythematous
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 mcg/kg
Indication: Hepatitis C
Rebetol
Dosage: 1 g, qd
Administration route: Oral
Indication: Hepatitis C
Telavic
Dosage: 2.25 g, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-04
Other drugs received by patient: Rabeprazole Sodium; Talion (Bepotastine Besylate); Amlodipine Besylate; Loxonin
Possible PEG-Intron side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-25
Patient:
Reactions: Gastrointestinal Haemorrhage, Anaemia, Haematemesis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2011-11-02
End date: 2012-06-27
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2011-11-02
End date: 2012-05-28
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-05-29
End date: 2012-06-30
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Start date: 2012-05-14
End date: 2012-05-22
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-05-23
End date: 2012-06-30
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-09
End date: 2012-05-11
Possible PEG-Intron side effects in
Reported by a physician from United States on 2012-08-24
Patient:
Reactions: Blood Disorder, Underdose
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Possible PEG-Intron side effects in
Reported by a health professional (non-physician/pharmacist) from Belgium on 2012-08-24
Patient:
Reactions: Weight Decreased, Tongue Disorder, Anaemia, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 150 microgram, qw
Indication: Hepatitis C
Start date: 2012-04-24
End date: 2012-01-01
PEG-Intron
Dosage: 120 microgram, qw
Start date: 2012-01-01
Rebetol
Dosage: 2x 200 mg in the morning and 200 mg in the evening
Start date: 2012-08-09
Rebetol
Dosage: unk unk, bid
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-24
End date: 2012-01-01
Rebetol
Dosage: 600 mg in the morning and 400 mg in the evening
Administration route: Oral
Start date: 2012-01-01
End date: 2012-08-08
Other drugs received by patient: Vasexten; Januvia; Valsartan and Hydrochlorothiazide; Glucophage; Nobiten
Possible PEG-Intron side effects in 54 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-24
Patient: 54 year old female
Reactions: Anxiety Disorder, Nausea, Insomnia, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Indication: Hepatitis C
Start date: 2012-02-15
Ribavirin
Dosage: 400 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-15
End date: 2012-02-28
Ribavirin
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-02-29
End date: 2012-06-12
Ribavirin
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-06-13
End date: 2012-06-19
Ribavirin
Dosage: 600 mg, qd
Administration route: Oral
Start date: 2012-06-20
End date: 2012-07-31
VX-950
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-15
End date: 2012-02-21
VX-950
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-02-22
End date: 2012-05-08
Other drugs received by patient: Ursodiol; Loxonin; Loxonin; Omeprazole; Januvia; Loxonin
Possible PEG-Intron side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-24
Patient:
Reactions: Erythema Multiforme
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-04-18
End date: 2012-05-23
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
End date: 2012-05-30
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-18
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-18
End date: 2012-05-30
Other drugs received by patient: Enalapril Maleate
Possible PEG-Intron side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-24
Patient:
Reactions: Rash
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.4 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-05-30
End date: 2012-07-04
Prednisolone
Dosage: 50 mg, qd, formulation : por
Administration route: Oral
Start date: 2012-07-10
Prednisolone
Dosage: 20 mg, qd, formulation : por
Administration route: Oral
Start date: 2012-07-02
Prednisolone
Dosage: 10 mg, qd, formulation : por
Administration route: Oral
Start date: 2012-07-04
Prednisolone
Dosage: 20 mg, qd, formulation : por
Administration route: Oral
Start date: 2012-07-06
Prednisolone
Dosage: 60 mg, qd, formulation : por
Administration route: Oral
Start date: 2012-07-08
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-30
End date: 2012-06-12
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-06-13
End date: 2012-07-07
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-30
End date: 2012-07-07
Other drugs received by patient: Alendronate Sodium; Acetaminophen; Clobetasol Propionate; Kindavate; Levofloxacin; Allegra; Famotidine; Rabeprazole Sodium; Azunol (Sodium Gualenate)
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Cerebral Haemorrhage
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-06-05
Rebetol
Dosage: 200 mg, once
Administration route: Oral
Start date: 2012-07-03
Rebetol
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-05
End date: 2012-06-26
Rebetol
Administration route: Oral
Start date: 2012-07-03
Rebetol
Administration route: Oral
Start date: 2012-06-27
End date: 2012-07-02
Rebetol
Administration route: Oral
Start date: 2012-06-27
End date: 2012-07-02
Telavic
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-05
Other drugs received by patient: Claritin; Posterisan; Lobu; Ferrous Citrate
Possible PEG-Intron side effects in
Reported by a physician from United States on 2012-08-24
Patient:
Reactions: Intestinal Polyp, Gastrointestinal Haemorrhage
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Norvasc
PEG-Intron
Dosage: unk, qw
Indication: Hepatitis C
Start date: 2012-02-16
Ribavirin
Dosage: 600 mg, bid
Administration route: Oral
Telaprevir
Dosage: 750 mg, q8h
Administration route: Oral
Other drugs received by patient: Centrum (Minerals (Unspecified) (+) Vitamins (Unspecified)); Xanthophyll
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Blood Creatinine Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-03-07
Antiviral (Unspecified)
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-10
End date: 2012-03-06
Lorfenamin
Dosage: unk unk, unknown
Administration route: Oral
Indication: Product Used FOR Unknown Indication
End date: 2012-02-14
Lorfenamin
Dosage: 80mg/day, prn
Administration route: Oral
Indication: Prophylaxis
Start date: 2012-02-10
End date: 2012-02-14
PEG-Intron
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-02-10
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Start date: 2012-03-07
End date: 2012-03-13
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Start date: 2012-03-28
End date: 2012-04-03
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-03-14
End date: 2012-03-27
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-10
End date: 2012-03-06
Rebetol
Dosage: 500 mg, qd
Administration route: Oral
Start date: 2012-04-04
Telavic
Dosage: 1500 mg, once
Administration route: Oral
Start date: 2012-03-07
Telavic
Dosage: 2250 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-02-10
End date: 2012-03-06
Other drugs received by patient: Acetaminophen; Locoid; Topsym (Fluocinonide); Acetaminophen
Possible PEG-Intron side effects in
Reported by a individual with unspecified qualification from Japan on 2012-08-24
Patient:
Reactions: Pyelonephritis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-13
End date: 2012-04-24
PEG-Intron
Dosage: 1.5 ?g/kg, qw
Indication: Hepatitis C
End date: 2012-04-24
PEG-Intron
Dosage: 1.5mcg/kg/week
Start date: 2012-03-13
End date: 2012-04-24
PEG-Intron
Dosage: 1.5mcg/kg/week
Start date: 2012-05-08
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-04-03
End date: 2012-04-24
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Indication: Hepatitis C
End date: 2012-04-02
Rebetol
Administration route: Oral
Start date: 2012-03-13
End date: 2012-04-02
Telavic
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-13
End date: 2012-04-24
Other drugs received by patient: Lasix; Enalapril Maleate; Amlodipine; Amlodipine Besylate; Amlodipine Besylate; Enalapril Maleate; Lactic Acid; Amlodipine Besylate; Enalapril Maleate; Levothyroxine Sodium; Levothyroxine Sodium; Lasix; Rebamipide; Lansoprazole; Flomox; Lacb R; Rebamipide OD; Lansoprazole
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Bone Marrow Failure
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 0.08 unk, unk
Start date: 2012-06-14
End date: 2012-06-22
PEG-Intron
Dosage: 0.83 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-04-26
End date: 2012-05-01
PEG-Intron
Dosage: 0.21 microgram per kilogram, unk
Start date: 2012-05-30
PEG-Intron
Dosage: 0.42 microgram per kilogram, qw
Start date: 2012-05-02
End date: 2012-05-30
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-05-17
End date: 2012-06-28
Rebetol
Dosage: 400 unk, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-26
End date: 2012-05-16
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-26
End date: 2012-06-28
Other drugs received by patient: Talion (Bepotastine Besylate); Rabeprazole Sodium; Talion (Bepotastine Besylate); Allopurinol
Possible PEG-Intron side effects in
Reported by a health professional (non-physician/pharmacist) from Colombia on 2012-08-24
Patient:
Reactions: Lymphocytosis, Full Blood Count Abnormal, Thrombocytopenia, Bicytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: 80 microgram, unk
Indication: Hepatitis C
Start date: 2012-05-30
Rebetol
Dosage: 100 mg, unk
Administration route: Oral
Victrelis
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-05-30
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Vomiting
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
PEG-Intron
Dosage: unk unk, unknown
End date: 2012-04-16
PEG-Intron
Dosage: 1.5 ?g/kg, qw
Start date: 2012-03-14
End date: 2012-04-13
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-04-12
End date: 2012-04-16
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-14
End date: 2012-04-11
Telavic
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-04-14
End date: 2012-04-16
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-14
End date: 2012-04-12
Telavic
Dosage: 1750 mg, qd
Administration route: Oral
Start date: 2012-04-13
End date: 2012-04-13
Other drugs received by patient: Dextrose (+) Electrolytes (Unspecified) (+) Sodium Lactate; Cyanocobalamin (+) Pyridoxine Hydrochloride (+) Thiamine Disulfide; Urso 250; Amino Acids (Unspecified); Fladd; Amlodipine Besylate; Selbex; Myser (Cycloserine); Ascorbic Acid; Olopatadine HCL; Neomallermin TR; Marzulene ES; Lansoprazole; Ascorbic Acid (+) Vitamin B Complex
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Pancreatitis Acute, Amylase Increased, Anaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-17
End date: 2012-02-29
Antiviral (Unspecified)
Dosage: 1500 mg, qd
Administration route: Oral
Start date: 2012-03-01
End date: 2012-03-20
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-01-17
End date: 2012-03-27
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-01-31
End date: 2012-03-20
Rebetol
Dosage: 600 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-17
End date: 2012-01-30
Telavic
Dosage: 2250 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-17
End date: 2012-02-29
Telavic
Dosage: 1500 mg, once
Administration route: Oral
Start date: 2012-03-01
End date: 2012-03-20
Telavic
Dosage: unk
Other drugs received by patient: Glufast; Glufast; Tamiflu; Zantac; Primperan TAB; Tamiflu; Acetaminophen; Zantac
Possible PEG-Intron side effects in
Reported by a individual with unspecified qualification from Japan on 2012-08-24
Patient:
Reactions: Deafness, Dizziness, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 1500 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-26
End date: 2012-02-14
Antiviral (Unspecified)
Dosage: 750 mg, qd
Administration route: Oral
Start date: 2012-02-21
End date: 2012-03-07
PEG-Intron
Dosage: 1.5mcg/kg/week
Start date: 2012-02-23
End date: 2012-03-01
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-01-26
End date: 2012-02-09
Peginterferon Alfa-2B
Dosage: 1.5 microgram per kilogram, qw
Start date: 2012-02-23
End date: 2012-03-01
Peginterferon Alfa-2B
Dosage: 1.5 microgram per kilogram, qw
Indication: Hepatitis C
Start date: 2012-01-26
End date: 2012-02-09
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-02-09
End date: 2012-03-07
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-26
End date: 2012-02-08
Telavic
Dosage: 1500 mg, once
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-01-26
End date: 2012-02-14
Telavic
Dosage: 750 mg, once
Administration route: Oral
Start date: 2012-02-21
End date: 2012-03-07
Other drugs received by patient: Diovan; Rebamipide; Urso 250; Proheparum; Nifedipine CR Sawai; Primperan TAB; Famotidine; Famotidine; Loxoprofen; Loxoprofen; Valsartan and Hydrochlorothiazide; Diovan; Primperan TAB; Rebamipide; Famotidine; Famotidine; Glycyron; Sepamit
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Stevens-Johnson Syndrome
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Antiviral (Unspecified)
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-19
End date: 2012-05-14
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-03-19
End date: 2012-05-14
PEG-Intron
Dosage: dosage is uncertain during a day.
Start date: 2012-05-24
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-19
End date: 2012-04-29
Rebetol
Dosage: 400 mg, qd
Administration route: Oral
Start date: 2012-04-30
Rebetol
Dosage: dosage is uncertain during a day.
Administration route: Oral
Start date: 2012-05-24
Rebetol
Dosage: 200 mg, qd
Administration route: Oral
Start date: 2012-05-08
End date: 2012-05-14
Telavic
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-03-19
End date: 2012-05-14
Other drugs received by patient: Diovan; Nizatidine; Nizatidine; Loxonin; Diovan; Primperan TAB; Diclofenac Sodium; Allopurinol; Urso 250; Norvasc; Urso 250; Norvasc
Possible PEG-Intron side effects in
Reported by a physician from Japan on 2012-08-24
Patient:
Reactions: Renal Impairment, Vomiting, Nausea, Dizziness, General Physical Health Deterioration
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Glycyron
Dosage: 6 df, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-06-14
End date: 2012-07-04
PEG-Intron
Dosage: 1.5mcg/kg/week
Indication: Hepatitis C
Start date: 2012-04-10
End date: 2012-04-16
Rebetol
Dosage: 800 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-10
End date: 2012-04-12
Rebetol
Dosage: 600 mg, qd
Administration route: Oral
Start date: 2012-04-13
End date: 2012-04-16
Telavic
Dosage: 2250 mg, qd
Administration route: Oral
Indication: Hepatitis C
Start date: 2012-04-10
End date: 2012-04-16
Other drugs received by patient: Adalat CC; Olmesartan Medoxomil; Olmesartan Medoxomil; Loxonin; Loxonin; Adalat CC; Adalat CC; Glycyron; Doxazosin Mesylate; Metformin HCL; Kinedak; Adalat CC; Nesina; Loxonin; Potassium Chloride; Trichlormethiazide; Amaryl; Lendormin; Allopurinol; Trichlormethiazide; Vitamin E; Primperan TAB; Amaryl; Loxonin; Metformin HCL; Kinedak; Rohypnol; Doxazosin Mesylate; Nesina; Urso 250; Vitamin B12; Electrolytes (Unspecified) (+) Sodium Lactate; Lyrica; Lendormin D
Possible PEG-Intron side effects in
Reported by a physician from Argentina on 2012-08-24
Patient:
Reactions: Anaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Blinded Boceprevir
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
PEG-Intron
Dosage: 150 units
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-06
Peginterferon Alfa-2B
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
Placebo
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
Ribavirin
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
Ribavirin
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-12
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Start date: 2010-07-15
End date: 2011-01-13
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Start date: 2010-07-15
End date: 2011-01-13
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Start date: 2010-07-15
End date: 2011-01-13
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Indication: Hepatitis C
Start date: 2010-07-15
End date: 2011-01-13
Simvastatin
Dosage: 2400 mg, unk
Administration route: Oral
Start date: 2010-07-15
End date: 2011-01-13
Page 1 Next >>
|
